NASDAQ:RDHL - REDHILL BIOPHAR/S Stock Price, News & Analysis

$7.76
-0.10 (-1.27 %)
(As of 09/17/2019 04:00 PM ET)
Today's Range
$7.76
Now: $7.76
$8.04
50-Day Range
$6.57
MA: $7.27
$8.18
52-Week Range
$5.13
Now: $7.76
$9.57
Volume19,943 shs
Average Volume68,849 shs
Market Capitalization$170.22 million
P/E RatioN/A
Dividend YieldN/A
Beta1.29
RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases in the United States. It operates through two segments, Commercial Operations and Research & Development. The company's clinical-stage development programs comprise TALICIA, a drug that is in Phase III clinical trial for the helicobacter pylori infection; RHB-104 that is in Phase III clinical trials for crohn's disease, as well as that has completed Phase II clinical trial for multiple sclerosis; RHB-204 for pulmonary nontuberculous mycobacteria infections; BEKINDA 24 mg that has completed Phase III clinical trial for acute gastroenteritis and gastritis; BEKINDA 12 mg that has completed Phase II clinical trial for irritable bowel syndrome with diarrhea; RHB-106 for bowel preparation; and RHB-107 that has completed Phase II clinical trial for gastrointestinal and other solid tumors. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RDHL
CUSIPN/A
Phone972-3541-3131

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$8.36 million
Book Value$2.41 per share

Profitability

Net Income$-38,820,000.00
Net Margins-561.47%

Miscellaneous

Employees75
Market Cap$170.22 million
Next Earnings Date11/12/2019 (Estimated)
OptionableOptionable

Receive RDHL News and Ratings via Email

Sign-up to receive the latest news and ratings for RDHL and its competitors with MarketBeat's FREE daily newsletter.


REDHILL BIOPHAR/S (NASDAQ:RDHL) Frequently Asked Questions

What is REDHILL BIOPHAR/S's stock symbol?

REDHILL BIOPHAR/S trades on the NASDAQ under the ticker symbol "RDHL."

How were REDHILL BIOPHAR/S's earnings last quarter?

REDHILL BIOPHAR/S (NASDAQ:RDHL) released its quarterly earnings results on Tuesday, July, 23rd. The biotechnology company reported ($0.38) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.32) by $0.06. The biotechnology company had revenue of $1.56 million for the quarter, compared to analyst estimates of $2.23 million. REDHILL BIOPHAR/S had a negative net margin of 561.47% and a negative return on equity of 93.55%. View REDHILL BIOPHAR/S's Earnings History.

When is REDHILL BIOPHAR/S's next earnings date?

REDHILL BIOPHAR/S is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for REDHILL BIOPHAR/S.

What price target have analysts set for RDHL?

4 equities research analysts have issued 1-year price objectives for REDHILL BIOPHAR/S's stock. Their predictions range from $16.00 to $24.00. On average, they expect REDHILL BIOPHAR/S's stock price to reach $20.00 in the next year. This suggests a possible upside of 157.7% from the stock's current price. View Analyst Price Targets for REDHILL BIOPHAR/S.

What is the consensus analysts' recommendation for REDHILL BIOPHAR/S?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for REDHILL BIOPHAR/S in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for REDHILL BIOPHAR/S.

Has REDHILL BIOPHAR/S been receiving favorable news coverage?

Press coverage about RDHL stock has been trending negative on Tuesday, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. REDHILL BIOPHAR/S earned a daily sentiment score of -2.9 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for REDHILL BIOPHAR/S.

Who are some of REDHILL BIOPHAR/S's key competitors?

What other stocks do shareholders of REDHILL BIOPHAR/S own?

Who are REDHILL BIOPHAR/S's key executives?

REDHILL BIOPHAR/S's management team includes the folowing people:
  • Mr. Dror Ben-Asher, Co-Founder, Chairman & CEO (Age 53)
  • Mr. Micha Ben-Chorin, Chief Financial Officer (Age 50)
  • Mr. Gilead Raday, Chief Operating Officer (Age 44)
  • Mr. Adi Frish, Sr. VP of Bus. Devel. & Licensing (Age 49)
  • Mr. Guy Goldberg, Chief Bus. Officer (Age 43)

Who are REDHILL BIOPHAR/S's major shareholders?

REDHILL BIOPHAR/S's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Ibex Investors LLC (8.51%), Morgan Stanley (0.38%), ARK Investment Management LLC (0.27%), Jane Street Group LLC (0.27%), Menta Capital LLC (0.26%) and Sanders Morris Harris LLC (0.23%).

Which institutional investors are selling REDHILL BIOPHAR/S stock?

RDHL stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Menta Capital LLC, ARK Investment Management LLC, D.A. Davidson & CO. and Van ECK Associates Corp.

Which institutional investors are buying REDHILL BIOPHAR/S stock?

RDHL stock was purchased by a variety of institutional investors in the last quarter, including Ibex Investors LLC, Jane Street Group LLC, Sanders Morris Harris LLC and ETF Managers Group LLC.

How do I buy shares of REDHILL BIOPHAR/S?

Shares of RDHL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is REDHILL BIOPHAR/S's stock price today?

One share of RDHL stock can currently be purchased for approximately $7.76.

How big of a company is REDHILL BIOPHAR/S?

REDHILL BIOPHAR/S has a market capitalization of $170.22 million and generates $8.36 million in revenue each year. The biotechnology company earns $-38,820,000.00 in net income (profit) each year or ($1.70) on an earnings per share basis. REDHILL BIOPHAR/S employs 75 workers across the globe.View Additional Information About REDHILL BIOPHAR/S.

What is REDHILL BIOPHAR/S's official website?

The official website for REDHILL BIOPHAR/S is http://www.redhillbio.com/.

How can I contact REDHILL BIOPHAR/S?

REDHILL BIOPHAR/S's mailing address is 21 HA`ARBA`A STREET, TEL AVIV L3, 64739. The biotechnology company can be reached via phone at 972-3541-3131.


MarketBeat Community Rating for REDHILL BIOPHAR/S (NASDAQ RDHL)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  348 (Vote Outperform)
Underperform Votes:  234 (Vote Underperform)
Total Votes:  582
MarketBeat's community ratings are surveys of what our community members think about REDHILL BIOPHAR/S and other stocks. Vote "Outperform" if you believe RDHL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDHL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/17/2019 by MarketBeat.com Staff

Featured Article: Candlestick

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel